Why the study?
Do pharmacologic agents reduce cardiovascular morbidity and mortality in patients with primary hypertension?
Do pharmacologic agents reduce cardiovascular morbidity and mortality in patients with primary hypertension?
Pharmacologic reduction of blood pressure in primary hypertension effectively reduces cardiovascular morbidity and mortality, with targets as low as tolerated without symptomatic hypotension.
Answers are grounded in this paper and cite their sources.
Supports antihypertensive therapy to reduce CV events in primary hypertension; confirms consensus while leaving optimal targets and agents open to further study.
Evidence summarized in the first part of this review indicates that reducing elevated blood pressure by administration of pharmacologic agents is effective in reducing the morbidity and mortality of cardiovascular disease associated with hypertension. Although still incomplete, the evidence also suggests that the objective of treatment should be reduction of blood pressure to as low a value as can be achieved without producing symptomatic hypotension. It is probable that the earlier treatment is instituted, and the more consistently blood pressure is maintained at a reduced level, the greater will be the effect in reducing the risk of vascular disease. There . . .
No takes yet. Share an insight, caveat, or question.
Page et al. (1972) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: